NRG-103 / Nurenje Biomedical Technology - LARVOL DELTA

A clinical trial evaluating the tolerability, safety, and preliminary efficacy of NRG-103 injection in patients with relapsed or advanced high-grade glioma (ChiCTR) - P=N/A | N=24 | Not yet recruiting | Sponsor: Huashan Hospital, Fudan University; Huashan Hospital, Fudan University

New trial • Brain Cancer • Glioma • High Grade Glioma • Oncology • Solid Tumor

A Clinical Trial Evaluating the Tolerability, Safety, and Preliminary Efficacy of NRG-103 Injection in Patients With Recurrent or Progressive High-grade Glioma (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: Neuregen Therapeutics Co., Ltd.

New P1 trial • Brain Cancer • Glioma • High Grade Glioma • Oncology • Solid Tumor

Clinical study on the safety and efficacy of NRG-103 injection in the treatment of recurrent glioblastoma patients (ChiCTR) - P=N/A | N=15 | Recruiting | Sponsor: Zhongnan Hospital of Wuhan University; Zhongnan Hospital of Wuhan University

New trial • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor

Safety and Efficacy of NRG-103 Injection in the Treatment of Recurrent Glioblastoma Patients (clinicaltrials.gov) - P1 | N=15 | Recruiting | Sponsor: Zhongnan Hospital

New P1 trial • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor